Về công ty

Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.

CH
Không xác định
Không xác định
Chưa xác minh công ty